Axiogenesis is a leading provider of unlimited volumes of pure human cell types derived from induced pluripotent stem cells (iPSC) along with assays validated on all relevant commercial platforms. Key products include cardiomyocytes used in applications from single cell analysis to HTS in early cardiac safety and efficacy, as well as several neural subtypes. We also offer services for in vitro toxicology, safety pharmacology and drug discovery. A strong IP position and key licenses enable us to offer FTO in the use of iPSC derived cells including disease models like cardiac hypertrophy (HCM).
Categories: Assays, Cell Culture, Contract Services, Drug Discovery, HTS Products